Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aptamer Group Plc ( (GB:APTA) ) has shared an update.
Aptamer Group has launched a targeted radiopharmaceutical development programme in collaboration with Radiopharmium Ltd, aiming to build a proprietary pipeline of Optimer®-based radioconjugates against three high‑value therapeutic targets. The initiative complements an existing partnership with a top‑three global pharma company and is expected to expand the firm’s radiotherapy pipeline to four assets, with in vivo data targeted by the end of 2026.
The company highlights internal data showing Optimer® radioligands exhibiting substantially improved stability versus leading peptide comparators when carrying Lu‑177, which could extend shelf life and simplify manufacturing and logistics if confirmed in further studies. The programme will be led by radiopharmaceutical expert Dr Louis Allott, whose consultancy Radiopharmium will provide radiochemistry and preclinical model access, reinforcing Aptamer’s efforts to differentiate its platform and strengthen its positioning in the fast‑growing targeted radiopharmaceuticals market.
The most recent analyst rating on (GB:APTA) stock is a Hold with a £0.79 price target. To see the full list of analyst forecasts on Aptamer Group Plc stock, see the GB:APTA Stock Forecast page.
Spark’s Take on APTA Stock
According to Spark, TipRanks’ AI Analyst, APTA is a Neutral.
The score is held back primarily by very weak financial performance (sharp revenue decline, ongoing losses, and negative cash flows). Technicals are the main offset, showing a clear uptrend with supportive momentum. Valuation remains constrained by unprofitability and the absence of dividend information.
To see Spark’s full report on APTA stock, click here.
More about Aptamer Group Plc
Aptamer Group plc is a UK-based life sciences company that develops next‑generation synthetic binders, branded as Optimer®, for use across research, diagnostics and therapeutics. The Group focuses on creating targeted biologic tools and drug modalities, and is increasingly positioning its Optimer® platform for applications in high‑growth areas such as radiopharmaceuticals and radioligand therapies.
Average Trading Volume: 4,775,126
Technical Sentiment Signal: Sell
Current Market Cap: £22.25M
Learn more about APTA stock on TipRanks’ Stock Analysis page.